GENFIT Appoints New CMO to Drive Clinical Development Strategy
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Nov 27 2025
0mins
Source: Globenewswire
- New Chief Medical Officer: GENFIT announces the appointment of Dr. Pejvack Motlagh as the new Chief Medical Officer, who will oversee the company's clinical development strategy and execution, expected to enhance the company's R&D capabilities in liver diseases.
- Extensive Industry Experience: Dr. Motlagh brings over 20 years of experience in the pharmaceutical and biotechnology sectors, having served as CMO at several large pharmaceutical and innovative biotech firms, which will provide deep expertise to GENFIT's clinical programs.
- Focus on Liver Disease Treatment: At a pivotal moment when Acute on-Chronic Liver Failure is gaining attention in the liver disease community, Dr. Motlagh's leadership is anticipated to drive GENFIT's innovation and patient-centric development, addressing high unmet medical needs.
- CEO's Expectations: GENFIT's CEO Pascal Prigent stated that Dr. Motlagh's leadership will be crucial for advancing the pipeline and fulfilling the mission to deliver transformative therapies, reflecting the company's confidence in future growth.
Get Free Real-Time Notifications for Any Stock
Monitor tickers like undefined with instant alerts to capture every critical market movement.
Sign up for free to build your custom watchlist and receive professional-grade stock notifications.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
